GO analysis of stage-salient genes in the order of decreasing significance (i.e, increasing p–value). by Sangeetha Muthamilselvan (8966006)

The relative change in incident cases of RA among AYAs between 1990 and 2019. by Ruibo Li (2063167)

Frequencies of peripheral blood immune cells with each profile in all patients before and after OBV/PTV/r therapy that did not change significantly. by Miyabi Miura (18605126)

Subjects:

Frequencies of peripheral blood immune cells with each profile in SVR and non-SVR cases. by Miyabi Miura (18605126)

Subjects:

TBX21 determination from candidate genes by PD-1+Treg- or PD-1+CD8+-related immune profile. by Miyabi Miura (18605126)

Subjects:

Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width. by Maral Budak (6680351)

“…(B) Comparison of CAP measures of synaptopathy cases relative to normal (no synaptopathy) at 70 dB SPL (*p<0.05, **p<0.01, #p<0.001). …”

Frequencies of peripheral blood immune cells with each profile in SVR and non-SVR cases for DCV/ASV treatment. by Miyabi Miura (18605126)

Subjects:

Frequencies of peripheral blood immune cells with each profile in the SVR cases before and after OBV/PTV/r treatment. by Miyabi Miura (18605126)

Subjects:

Expression pattern of statistically significantly differentially expressed immune-related genes in CL patients compared to healthy volunteers. by Nasrin Masoudzadeh (20300511)

“…The red and blue colors of the bar plot represent relative significant increased or decreased expression of the genes in patients compared to healthy samples. …”

Degeneration Saline group presented with significant decreased final weight in relation to other groups. by Flavia Gomes Velasque Gama (21175112)

Estimated short- and long-term cumulative changes in CRC incidence and CRC mortality attributable to screening, diagnosis, and treatment decreases in 2020 and 2021. by Joachim Worthington (8394213)

Subjects:

Comparison of all–age cases with age–standardized incidence, prevalence,deaths, and DALYs in global men and women, 1990–2021. by Zhengpeng Li (2322058)

Subjects:

Comparison of all–age cases with age–standardized incidence, prevalence,deaths, and DALYs in Chinese men and women, 1990–2021. by Zhengpeng Li (2322058)

Subjects:

Frequencies of peripheral blood immune cells with each profile in SVR patients before and after OBV/PTV/r therapy by paired comparison analysis for each patient. by Miyabi Miura (18605126)

Subjects:

Consolidated standard of reporting trials (CONSORT) diagram. by Miyabi Miura (18605126)

Subjects:

Raw data of frequencies of peripheral blood immune cells with each profile for DCV/ASV treatment. by Miyabi Miura (18605126)

Subjects:

Frequencies of peripheral blood immune cells with each profile in the non-SVR group before and after OBV/PTV/r therapy. by Miyabi Miura (18605126)

Subjects:

Frequencies of peripheral blood immune cells with each profile in all patients before and after OBV/PTV/r therapy by paired comparison analysis for each patient. by Miyabi Miura (18605126)

Subjects:

Frequencies of peripheral blood immune cells with each profile in patients before and after DCV/ASV therapy. by Miyabi Miura (18605126)

Subjects:

Consolidated standard of reporting trials (CONSORT) diagram. by Miyabi Miura (18605126)

Subjects: